
Lasofoxifene Tartrate
CAS No. 190791-29-8
Lasofoxifene Tartrate( CP-336156 )
Catalog No. M21094 CAS No. 190791-29-8
Lasofoxifene Tartrate?is a third-generation non-steroidal selective estrogen receptor modulator.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 48 | Get Quote |
![]() ![]() |
10MG | 65 | Get Quote |
![]() ![]() |
25MG | 128 | Get Quote |
![]() ![]() |
50MG | 230 | Get Quote |
![]() ![]() |
100MG | 300 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameLasofoxifene Tartrate
-
NoteResearch use only, not for human use.
-
Brief DescriptionLasofoxifene Tartrate?is a third-generation non-steroidal selective estrogen receptor modulator.
-
DescriptionLasofoxifene Tartrate?is a third-generation non-steroidal selective estrogen receptor modulator.(In Vitro):Lasofoxifene tartrate (1 nM-1 μM; 48 h) shows antagonist activity on ER+ breast cancer cells without being affected by the expression level of activating ERα mutants relative to wild-type (WT) ERα.(In Vivo):Lasofoxifene tartrate (4 mg/mice; s.c.; 5 day/week; for 43 d) decreases arthritis severity, by reducing cartilage oligomeric matrix protein (COMP), the serum marker of cartilage destruction and reducing serum IL-6 (inflammatory cytokine) levels.Lasofoxifene tartrate (4 mg/mice; s.c.; 5 day/week; for 43 d) protects against generalised bone loss in CIA by increasing trabecular bone mineral density (BMD), cortical thickness in mice.Lasofoxifene tartrate (5, and 10 mg/kg; s.c.; 5 day/week; for 70 d) exerts function of inhibiting primary tumor growth and reducing metastases to the lung and the liver in mice.
-
In VitroLasofoxifene tartrate (1 nM-1 μM; 48 h) shows antagonist activity on ER+ breast cancer cells without being affected by the expression level of activating ERα mutants relative to wild-type (WT) ERα.
-
In VivoLasofoxifene tartrate (4 mg/mice; s.c.; 5 day/week; for 43 d) decreases arthritis severity, by reducing cartilage oligomeric matrix protein (COMP), the serum marker of cartilage destruction and reducing serum IL-6 (inflammatory cytokine) levels.Lasofoxifene tartrate (4 mg/mice; s.c.; 5 day/week; for 43 d) protects against generalised bone loss in CIA by increasing trabecular bone mineral density (BMD), cortical thickness in mice.Lasofoxifene tartrate (5, and 10 mg/kg; s.c.; 5 day/week; for 70 d) exerts function of inhibiting primary tumor growth and reducing metastases to the lung and the liver in mice. Animal Model:Post-menopausal RA model on OVX (ovariectomised) DBA/1 mice (female DBA/1 mice, 8-10 weeks old, CIA-treated) Dosage:4 mg/mouse/day Administration:Subcutaneous injection; 5 days a week from the first signs of arthritis (day 18); 43 days Result:Reduced in arthritis severity, including synovial inflammation and destruction of joints reduction.The mean arthritis frequency was 47% while the vehicle group was 81% at 42 days post immunization.Animal Model:NSG mices with xenograft tumors model (MIND, mammary intraductal): WT, Y537S and D538G ERα render tumors Dosage:1, 5, or 10 mg/kg Administration:Subcutaneous injection; 5 days per week; for 70 days Result:Elicited a superior inhibitory effect at a dose of 10 mg/kg, resulted potential tumor shrinkage in Y537S and D538G tumors. And also reduced tumor weight to 60% for Y537S and 50% for D538G at 5 and 10 mg/kg, respectively.
-
SynonymsCP-336156
-
PathwayEndocrinology/Hormones
-
TargetEstrogen Receptor/ERR
-
Recptoroestrogen receptor
-
Research AreaCancer
-
IndicationLocally Advanced or Metastatic Breast Cancer
Chemical Information
-
CAS Number190791-29-8
-
Formula Weight563.64
-
Molecular FormulaC32H37NO8
-
Purity>98% (HPLC)
-
SolubilityDMSO:6 mg/mL (10.65 mM)
-
SMILESO=C(O)C(O)C(O)C(=O)O.Oc1ccc2c(c1)CCC(c1ccccc1)C2c1ccc(OCCN2CCCC2)cc1
-
Chemical Name(5R6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5678-tetrahydronaphthalen-2-ol
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Andersson A Bernardi A I Stubelius A et al. Selective oestrogen receptor modulators lasofoxifene and bazedoxifene inhibit joint inflammation and osteoporosis in ovariectomised mice with collagen-induced arthritis[J]. Rheumatology 2015:kev355.
molnova catalog



related products
-
Megestrol acetate
Megestrol acetate is a progestogen with actions and uses similar to those of the progestogens in general.
-
4-Hydroxyestrone
4-Hydroxyestrone, an endogenous estrogen metabolite, can strongly protect neuronal cells against oxidative damage.
-
N-Desmethyltamoxifen...
N-Desmethyltamoxifen hydrochloride is the major tamoxifen metabolite in humans.